MAZE Stock Analysis: Maze Therapeutics, Common | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 1.650m USD | 12M Return: 171% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 19.0M
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 1.4 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Maze Therapeutics, Inc. (NASDAQ: MAZE) is a clinical-stage biopharmaceutical company based in South San Francisco, California, focused on developing oral small molecule precision medicines for kidney and metabolic diseases. The company was incorporated in 2017 (formerly Modulus Therapeutics) and completed its IPO on January 31, 2025. Its lead clinical assets include MZE829, a Phase II oral APOL1 inhibitor for APOL1 kidney disease, and MZE782, a Phase II-ready candidate targeting phenylketonuria and chronic kidney disease. Additional pipeline programs include MZE001 for Pompe disease, with development and commercialization rights licensed to Shionogi.
The company supports its research operations through multiple discovery and commercialization partnerships, including agreements with Trace Neuroscience (UNC13A targets), Shionogi (MZE001), and Neurocrine Biosciences (ATXN2 program). As a clinical-stage firm in the pharmaceuticals sub-industry, Maze Therapeutics relies on a small-molecule, target-driven development model typical of precision medicine companies, where revenue is not yet generated from approved products but is supplemented by milestone payments, royalties, and collaboration funding from larger biopharma partners.
- MZE829 Phase II APOL1 kidney disease data readout
- Shionogi partnership monetizes MZE001 Pompe program
- Cash runway from IPO funds pipeline through key milestones
| Net Income: -122.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.24 > 0.02 and ΔFCF/TA -43.33 > 1.0 |
| NWC/Revenue: 1.79k% < 20% (prev 167.8%; Δ 1.62k% < -1%) |
| CFO/TA -0.29 > 3% & CFO -121.5m > Net Income -122.5m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 17.88 > 1.5 & < 3 |
| Outstanding Shares: last quarter (53.9m) vs 12m ago 23.06% < -2% |
| Gross Margin: 87.98% > 18% (prev 98.03%; Δ -10.05% > 0.5%) |
| Asset Turnover: 5.32% > 50% (prev 50.32%; Δ -45.01% > 0%) |
| Interest Coverage Ratio: -140.5 > 6 (EBIT TTM -121.7m / Interest Expense TTM 866k) |
| A: 0.85 (Total Current Assets 379.8m - Total Current Liabilities 21.2m) / Total Assets 419.7m |
| B: -1.22 (Retained Earnings -513.8m / Total Assets 419.7m) |
| C: -0.32 (EBIT TTM -121.7m / Avg Total Assets 376.3m) |
| D: 4.38 (Book Value of Equity 341.7m / Total Liabilities 78.0m) |
| Altman-Z'' = 4.04 = AA |
As of July 08, 2026, the stock is trading at USD 32.84 with a total of 621,710 shares traded. Over the past week, the price has changed by +13.24%, over one month by +39.27%, over three months by +15.92% and over the past year by +170.96%.
Current recommended Stop Loss: 31.00 (which is 5.6% or 1.3 ATR below the current price).
Maze Therapeutics, Common has received a consensus analysts rating of 4.75. Therefore, it is recommended to buy MAZE.
- StrongBuy: 3
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 62.6 | 90.5% |
P/E Forward = 8.5324
P/S = 82.4921
P/B = 4.8218
Revenue TTM = 20.0m USD
EBIT TTM = -121.7m USD
EBITDA TTM = -119.5m USD
Long Term Debt = 38.8m USD (from longTermDebt, last quarter)
Short Term Debt = 4.84m USD (from shortTermDebt, last quarter)
Debt = 83.6m USD (from shortLongTermDebtTotal, last quarter) + Leases 22.4m
Net Debt = -268.8m USD (calculated: Debt 83.6m - CCE 352.4m)
Enterprise Value = 1.38b USD (1.65b + Debt 83.6m - CCE 352.4m)
Interest Coverage Ratio = -140.5 (Ebit TTM -121.7m / Interest Expense TTM 866k)
EV/FCF = -13.72x (Enterprise Value 1.38b / FCF TTM -100.7m)
FCF Yield = -7.29% (FCF TTM -100.7m / Enterprise Value 1.38b)
FCF Margin = -503.4% (FCF TTM -100.7m / Revenue TTM 20.0m)
Net Margin = -612.7% (Net Income TTM -122.5m / Revenue TTM 20.0m)
Gross Margin = 87.98% ((Revenue TTM 20.0m - Cost of Revenue TTM 2.40m) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 3.29 (Enterprise Value 1.38b / Total Assets 419.7m)
Interest Expense / Debt = 1.04% (Interest Expense 866k / Debt 83.6m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -96.1m (EBIT -121.7m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 15.04 (Total Current Assets 379.8m / Total Current Liabilities 25.2m)
Debt / Equity = 0.24 (Debt 83.6m / totalStockholderEquity, last quarter 341.7m)
Debt / EBITDA = 2.25 (negative EBITDA) (Net Debt -268.8m / EBITDA -119.5m)
Debt / FCF = 2.67 (negative FCF - burning cash) (Net Debt -268.8m / FCF TTM -100.7m)
Total Stockholder Equity = 334.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -32.57% (Net Income -122.5m / Total Assets 419.7m)
RoE = -36.63% (Net Income TTM -122.5m / Total Stockholder Equity 334.6m)
RoCE = -32.58% (EBIT -121.7m / Capital Employed (Equity 334.6m + L.T.Debt 38.8m))
RoIC = -23.89% (negative operating profit) (NOPAT -96.1m / Invested Capital 402.3m)
WACC = 9.60% (E(1.65b)/V(1.73b) * Re(10.04%) + D(83.6m)/V(1.73b) * Rd(1.04%) * (1-Tc(0.21)))
Discount Rate = 10.04% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 43.19 | Cagr: 9.68%
[DCF] Fair Price = unknown (Cash Flow -100.7m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.02 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: N/A | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.70 | Chg30d=+2.71% | Revisions=+10% | Analysts=8
EPS next Quarter (2026-09-30): EPS=-0.75 | Chg30d=+3.66% | Revisions=-10% | Analysts=8
EPS current Year (2026-12-31): EPS=-2.67 | Chg30d=+3.47% | Revisions=+0% | GrowthEPS=+12.4% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-3.19 | Chg30d=+3.58% | Revisions=+10% | GrowthEPS=-19.4% | GrowthRev=-55.8%
[Analyst] Revisions Ratio: +3% (up=14, down=13)